Improved Disease-modifying Therapies for CNS Diseases

Acelot is a drug discovery company focusing on finding effective disease-modifying therapies with minimal side-effects for central nervous system diseases such as Alzheimer's and Parkinson's Disease.

Acelot's core advantage is a patented computer-aided drug target and lead discovery technology. It allows for the discovery of novel lead compounds directed to known targets and previously unknown drug targets within large biochemical pathways. The algorithms Acelot uses screen against undesired pathways and targets, thereby minimizing the risk of side-effects.

The current drug discovery pipeline includes the following mechanisms-of-action:

amyloid rxr lxr
Beta-amyloid oligomer antagonists (Alzheimer's Disease) RXR agonists (Alzheimer's Disease) LXR/PPAR modulators (Alzheimer's Disease)


December 3, 2013
Congresswoman Lois Capps (CA-24) highlights Acelot's recently funded project on building a web-based drug discovery platform as an example of applying innovation to the nation's healthcare needs. Read more here.

November 29, 2013
Acelot has been awarded a prestigious SBIR Grant from the National Science Foundation to build a cloud-based, "learning" drug discovery platform based on Acelot's unique graph-based mining algorithms.

November 9, 2013
Acelot presented a poster entitled "Joint Pharmacophore Space Mining for Central Nervous System Drug Discovery" on the JPS approach at the 43rd Annual Meeting of the Society for Neuroscience, Nov 9-13, San Diego.